105 related articles for article (PubMed ID: 1725104)
21. Importance of glycoproteins in human cancer.
Patel PS; Raval GN; Rawal RM; Patel MM; Balar DB; Patel DD
Indian J Biochem Biophys; 1997; 34(1-2):226-33. PubMed ID: 9343956
[TBL] [Abstract][Full Text] [Related]
22. [The clinical value of tissue polypeptide antigen in ovarian carcinoma].
Wu L; Sun J; Wang X
Zhonghua Fu Chan Ke Za Zhi; 1998 Feb; 33(2):92-4. PubMed ID: 10682428
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of circulating immune complexes and serum immunoglobulins in oral cancer patients--a follow up study.
Parveen S; Taneja N; Bathi RJ; Deka AC
Indian J Dent Res; 2010; 21(1):10-5. PubMed ID: 20427899
[TBL] [Abstract][Full Text] [Related]
24. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer.
Brakora KA; Lee H; Yusuf R; Sullivan L; Harris A; Colella T; Seiden MV
Gynecol Oncol; 2004 May; 93(2):361-5. PubMed ID: 15099946
[TBL] [Abstract][Full Text] [Related]
25. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
[TBL] [Abstract][Full Text] [Related]
26. Significance of the O6-methylguanine-DNA methyltransferase and glutathione S-transferase activity in the sera of patients with malignant and benign ovarian tumors.
Akçay T; Dinçer Y; Alademir Z; Aydinli K; Arvas M; Demirkiran F; Kösebay D
Eur J Obstet Gynecol Reprod Biol; 2005 Mar; 119(1):108-13. PubMed ID: 15734094
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
[TBL] [Abstract][Full Text] [Related]
28. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A
Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859
[TBL] [Abstract][Full Text] [Related]
29. Circulating immune complexes detected by a direct nephelometric assay and acute phase proteins in malignant tumors.
Bartoloni C; Guidi L; Baroni R; Tricerri A; Gentiloni N; Barone C; Gambassi G
Allerg Immunol (Paris); 1990 Dec; 22(10):411-6. PubMed ID: 1705126
[TBL] [Abstract][Full Text] [Related]
30. Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA-125) in the early prediction of recurrent ovarian cancer.
Yeh LS; Hung YC; Kao A; Lin CC; Lee CC
Anticancer Res; 2002; 22(6B):3669-71. PubMed ID: 12552974
[TBL] [Abstract][Full Text] [Related]
31. [Circulating lipid-bound sialic acid levels in patients with malignant tumors].
Bassalyk LS; Novikov AM; Sokolova VD; Sorokin EN
Vopr Med Khim; 1984; 30(3):124-7. PubMed ID: 6474937
[TBL] [Abstract][Full Text] [Related]
32. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
33. [Clinical significance of sialic acid determinations in patients with gynecologic cancer].
Shimizu Y; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Kurachi K; Okudaira Y
Nihon Sanka Fujinka Gakkai Zasshi; 1987 Jan; 39(1):49-55. PubMed ID: 3819514
[TBL] [Abstract][Full Text] [Related]
34. A comparative study of immunosuppressive acidic protein (IAP), CA 125 and acute-phase proteins as parameters for ovarian cancer monitoring.
Koebl H; Tatra G; Bieglmayer C
Neoplasma; 1988; 35(2):215-20. PubMed ID: 3259680
[TBL] [Abstract][Full Text] [Related]
35. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
36. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.
Lokshin AE; Winans M; Landsittel D; Marrangoni AM; Velikokhatnaya L; Modugno F; Nolen BM; Gorelik E
Gynecol Oncol; 2006 Aug; 102(2):244-51. PubMed ID: 16434085
[TBL] [Abstract][Full Text] [Related]
37. [Results of CA-125 tumor marker determination in patients with ovarian carcinoma].
Miladinović D; Paunović R; Paunković N
Jugosl Ginekol Perinatol; 1989; 29(3-4):83-5. PubMed ID: 2601371
[TBL] [Abstract][Full Text] [Related]
38. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms.
Harłozinska A; Sedlaczek P; Van Dalen A; Rozdolski K; Einarsson R
Anticancer Res; 1997; 17(6D):4473-8. PubMed ID: 9494553
[TBL] [Abstract][Full Text] [Related]
39. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
Suzuki M; Ohwada M; Aida I; Tamada T; Hanamura T; Nagatomo M
Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270
[TBL] [Abstract][Full Text] [Related]
40. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
